Status:
ACTIVE_NOT_RECRUITING
Treatment Duration of IPA
Lead Sponsor:
Peking University People's Hospital
Conditions:
Invasive Aspergillosis
Antifungal Therapy
Eligibility:
All Genders
Brief Summary
The goal of this observational study is to identify the duration of posaconazole-initiated antifungal treatment for IPA in patients with hematological malignancies and to explore the value of monitori...
Detailed Description
1. A total of 15 patients will be involved in the study. 2. For each patient, the investigator will first evaluate the patient to determine if the patient meets the enrollment criteria and does not me...
Eligibility Criteria
Inclusion
- Informed consent form signed
- Patient with hematological malignancies
- Patients with posaconazole-initiated antifungal therapy
- Treatment duration ≥12w
Exclusion
- Refuse to enroll
- Pregnancy or breastfeeding women
- Are expected to survive no more than 72 h
- Fungal or mycobacterial lung co infection at time of IPA diagnosis
- Hematological malignancy with lung location
- Disseminated aspergillosis (lung and sinus aspergillosis can be included)
Key Trial Info
Start Date :
December 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2026
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT06583512
Start Date
December 1 2024
End Date
August 31 2026
Last Update
December 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100044